Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on November 12, 2020, reporting events as of November 11, 2020. The filing announces the release of financial results for the three and nine months ended September 30, 2020, along with recent corporate updates.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K.
Material Changes
No specific material changes versus prior periods are quantified in this document. The filing serves as a notification that results for the period ended September 30, 2020, have been reported.
Guidance, Outlook, and Risks
The filing includes "other recent corporate updates" but does not detail specific guidance, outlook, management commentary, risks, or contingencies in the text provided. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the specific financial figures (revenue, net loss, cash position) in the press release attached as Exhibit 99.1.
- Confirm the details of the "recent corporate updates" mentioned in the filing.
- Note that the registrant is Salarius Pharmaceuticals, Inc. (Ticker: SLRX), not Decoy Therapeutics Inc.
- Review the full text of Exhibit 99.1 for any forward-looking statements or risk factors not summarized in this 8-K.